Article

You have full text access to this OnlineOpen article

Listeriolysin O as cytotoxic component of an immunotoxin

  1. Sabine Bergelt,
  2. Stefan Frost,
  3. Hauke Lilie*

Article first published online: 7 APR 2009

DOI: 10.1002/pro.130

Issue

Protein Science

Protein Science

Volume 18, Issue 6, pages 1210–1220, June 2009

Additional Information

How to Cite

Bergelt, S., Frost, S. and Lilie, H. (2009), Listeriolysin O as cytotoxic component of an immunotoxin. Protein Science, 18: 1210–1220. doi: 10.1002/pro.130

Author Information

  1. Institute of Biotechnology, Martin-Luther-University, Halle-Wittenberg, 06120 Halle, Saale, Germany

*Institute of Biotechnology, Martin-Luther-University, Halle-Wittenberg, Kurt-Mothes Str. 3, 06120 Halle, Saale, Germany

Publication History

  1. Issue published online: 26 MAY 2009
  2. Article first published online: 7 APR 2009
  3. Accepted manuscript online: 7 APR 2009 12:00AM EST
  4. Manuscript Accepted: 5 MAR 2009
  5. Manuscript Revised: 21 FEB 2009
  6. Manuscript Received: 23 SEP 2008

Funded by

  • The Deutsche Forschungsgemeinschaft. Grant Number: SFB 610
  • The Land Sachsen-Anhalt

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (469K)

References

  • 1
    Schrama D, Reisfeld RA, Becker JC ( 2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5: 147–159.
  • 2
    Carter P ( 2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1: 118–129.
  • 3
    Kreitman RJ, Pastan I ( 1998) Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 31: 53–88.
  • 4
    FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I ( 2004) Recombinant immunotoxins for treating cancer. Int J Med Microbiol 293: 577–582.
  • 5
    Gaillard JL, Berche P, Mounier J, Richard S, Sansonetti P ( 1987) In vitro model of penetration and intracellular growth of Listeria monocytogenes in the human enterocyte-like cell line Caco-2. Infect Immun 55: 2822–2829.
  • 6
    Kuhn M, Kathariou S, Goebel W ( 1988) Hemolysin supports survival but not entry of the intracellular bacterium Listeria monocytogenes. Infect Immun 56: 79–82.
  • 7
    Vázquez-Boland JA, Kuhn M, Berche P, Chakraborty T, Domínguez-Bernal G, Goebel W, González-Zorn B, Wehland J, Kreft J ( 2001) Listeria pathogenesis and molecular virulence determinants. Clin Microbiol Rev 14: 584–640.
  • 8
    Schnupf P, Portnoy DA ( 2007) Listeriolysin O: a phagosome-specific lysin. Microbes Infect 9: 1176–1187.
  • 9
    Geoffroy C, Gaillard JL, Alouf JE, Berche P ( 1987) Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect Immun 55: 1641–1646.
  • 10
    Bayley H ( 1997) Toxin structure: part of a hole? Curr Biol 7: 763–767.
  • 11
    Palmer M ( 2001) The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 39: 1681–1689.
  • 12
    Tweten RK ( 2005) Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 73: 6199–6209.
  • 13
    Kayal S, Charbit A ( 2006) Listeriolysin O: a key protein of Listeria monocytogenes with multiple functions. FEMS Microbiol Rev 30: 514–529.
    Direct Link:
  • 14
    Bhakdi S, Tranum-Jensen J, Sziegoleit A ( 1985) Mechanism of membrane damage by streptolysin-O. Infect Immun 47: 52–60.
  • 15
    Rossjohn J, Feil SC, McKinstry WJ, Tweten RK, Parker MW ( 1997) Structure of a cholesterol-binding, thiol-activated cytolysin and a model of its membrane form. Cell 89: 685–692.
  • 16
    Michel E, Reich KA, Favier R, Berche P, Cossart P ( 1990) Attenuated mutants of the intracellular bacterium Listeria monocytogenes obtained by single amino acid substitutions in listeriolysin O. Mol Microbiol 4: 2167–2178.
    Direct Link:
  • 17
    Sekino-Suzuki N, Nakamura M, Mitsui KI, Ohno-Iwashita Y ( 1996) Contribution of individual tryptophan residues to the structure and activity of theta-toxin (perfringolysin O), a cholesterol-binding cytolysin. Eur J Biochem 241: 941–947.
    Direct Link:
  • 18
    Jacobs T, Cima-Cabal MD, Darji A, Méndez FJ, Vázquez F, Jacobs AA, Shimada Y, Ohno-Iwashita Y, Weiss S, de los Toyos JR ( 1999) The conserved undecapeptide shared by thiol-activated cytolysins is involved in membrane binding. FEBS Lett 459: 463–466.
  • 19
    Giammarini C, Andreoni F, Amagliani G, Casiere A, Barocci S, Magnani M ( 2003) High-level expression of the Listeria monocytogenes listeriolysin O in Escherichia coli and preliminary characterization of the purified protein. Protein Expr Purif 28: 78–85.
  • 20
    Glomski IJ, Gedde MM, Tsang AW, Swanson JA, Portnoy DA ( 2002) The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol 156: 1029–1038.
  • 21
    Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC ( 1991) Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 51: 3781–3787.
  • 22
    Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I ( 1993) A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 90: 7538–7542.
  • 23
    Jung SH, Pastan I, Lee BK ( 1994) Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins 19: 35–47.
    Direct Link:
  • 24
    Reiter Y, Pai LH, Brinkmann U, Wang QC, Pastan I ( 1994) Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res 54: 2714–2718.
  • 25
    Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon J, Bigner DD ( 1995) Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci USA 28: 2765–2769.
  • 26
    Richter SA, Stubenrauch K, Lilie H, Rudolph R ( 2001) Polyionic fusion peptides function as specific dimerization motifs. Protein Eng 14: 775–783.
  • 27
    Kleinschmidt M, Rudolph R, Lilie H ( 2003) Design of a modular immunotoxin connected by polyionic adapter peptides. J Mol Biol 327: 445–452.
  • 28
    Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, Lilie H, Jenne DE ( 2004) Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett 562: 87–92.
  • 29
    Stubenrauch K, Gleiter S, Brinkmann U, Rudolph R, Lilie H ( 2001) Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles. Biochem J 356: 867– 873.
  • 30
    May T, Gleiter S, Lilie H ( 2002) Assessment of cell type specific gene transfer of polyoma virus like particles presenting a tumor specific antibody Fv fragment. J Virol Methods 105: 147–157.
  • 31
    Adams GP, Weiner LM ( 2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147–1157.
  • 32
    Shen WC, Ballou B, Ryser HJ, Hakala TR ( 1986) Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. Cancer Res 46: 3912–3916.
  • 33
    Dillman RO, Johnson DE, Shawler DL, Koziol JA ( 1988) Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48: 6097–6102.
  • 34
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID ( 1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336–340.
  • 35
    Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL ( 1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14: 1974–1981.
  • 36
    Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID ( 1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678–3684.
  • 37
    Brinkmann U, Keppler-Hafkemeyer A, Hafkemeyer P ( 2001) Recombinant immunotoxins for cancer therapy. Expert Opin Biol Ther 1: 693–702.
  • 38
    Kreitman RJ ( 2006) Immunotoxins for targeted cancer therapy. AAPS J 8: 532–551.
  • 39
    Hexham JM, Dudas D, Hugo R, Thompson J, King V, Dowling C, Neville, DM,Jr, Digan ME, Lake P ( 2001) Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Mol Immunol 38: 397–408.
  • 40
    Frankel AE, Kreitman RJ, Sausville EA ( 2000) Targeted toxins. Clin Cancer Res 6: 326–334.
  • 41
    Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR ( 1988) Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 48: 6396–6403.
  • 42
    Saito G, Amidon GL, Lee KD ( 2003) Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential. Gene Ther 10: 72–83.
  • 43
    Giammarini C, Andreoni F, Amagliani G, Casiere A, Barocci S, Magnani M ( 2004) Purification and characterization of a recombinant listeriolysin O expressed in Escherichia coli and possible diagnostic applications. J Biotechnol 109: 13–20.
  • 44
    Roberg K, Johansson U, Ollinger K ( 1999) Lysosomal release of cathepsin D precedes relocation of cytochrome c and loss of mitochondrial transmembrane potential during apoptosis induced by oxidative stress. Free Radic Biol Med 27: 1228–1237.
  • 45
    Bursch W ( 2001) The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 8: 569–581.
  • 46
    Guzmán CA, Domann E, Rohde M, Bruder D, Darji A, Weiss S, Wehland J, Chakraborty T, Timmis KN ( 1996) Apoptosis of mouse dendritic cells is triggered by listeriolysin, the major virulence determinant of Listeria monocytogenes. Mol Microbiol 20: 119–126.
    Direct Link:
  • 47
    Carrero JA, Calderon B, Unanue ER ( 2004) Listeriolysin O from Listeria monocytogenes is a lymphocyte apoptogenic molecule. J Immunol 172: 4866– 4874.
  • 48
    Jacobs T, Darji A, Frahm N, Rohde M, Wehland J, Chakraborty T, Weiss S ( 1998) Listeriolysin O: cholesterol inhibits cytolysis but not binding to cellular membranes. Mol Microbiol 28: 1081–1089.
    Direct Link:
  • 49
    Rudolph R, Boehm G, Lilie H, Jaenicke R, Folding proteins. In: CreightonTE, Ed.( 1997) Protein function—a practical approach. Oxford: IRL Press, pp 57–99.
View Full Article (HTML) Get PDF (469K)